These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37005546)

  • 1. Circulating MicroRNAs: Diagnostic Value as Biomarkers in the Detection of Non-alcoholic Fatty Liver Diseases and Hepatocellular Carcinoma.
    Rana M; Saini M; Das R; Gupta S; Joshi T; Mehta DK
    Microrna; 2023; 12(2):99-113. PubMed ID: 37005546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Extracellular Vesicle-Derived microRNAs as Novel Diagnostic and Prognostic Biomarkers for Non-Viral-Related Hepatocellular Carcinoma.
    Boonkaew B; Satthawiwat N; Pinjaroen N; Chuaypen N; Tangkijvanich P
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.
    Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
    Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.
    Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
    Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.
    Li YJ; Baumert BO; Stratakis N; Goodrich JA; Wu HT; He JX; Zhao YQ; Aung MT; Wang HX; Eckel SP; Walker DI; Valvi D; La Merrill MA; Ryder JR; Inge TH; Jenkins T; Sisley S; Kohli R; Xanthakos SA; Baccarelli AA; McConnell R; Conti DV; Chatzi L
    World J Gastroenterol; 2024 Jan; 30(4):332-345. PubMed ID: 38313232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma.
    Afonso MB; Rodrigues PM; Simão AL; Castro RE
    J Clin Med; 2016 Mar; 5(3):. PubMed ID: 26950158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miRNAs in non-alcoholic fatty liver disease.
    He Z; Hu C; Jia W
    Front Med; 2016 Dec; 10(4):389-396. PubMed ID: 27680976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
    Hochreuter MY; Dall M; Treebak JT; Barrès R
    Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From NAFLD to HCC: Advances in noninvasive diagnosis.
    Xu Q; Feng M; Ren Y; Liu X; Gao H; Li Z; Su X; Wang Q; Wang Y
    Biomed Pharmacother; 2023 Sep; 165():115028. PubMed ID: 37331252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.
    Hwang A; Shi C; Zhu E; Naaz F; Zhou P; Rasheed Z; Liu M; Jung LS; Duan B; Li J; Jiang K; Paka L; Gadhiya SV; Dana D; Ali Q; Yamin MA; Goldberg ID; Narayan P
    PLoS One; 2018; 13(6):e0198937. PubMed ID: 29944670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive biomarkers in non-alcoholic steatohepatitis-induced hepatocellular carcinoma.
    Voiculescu M; Nanau RM; Neuman MG
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):425-9. PubMed ID: 25532002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating miRNAs associated with nonalcoholic fatty liver disease.
    Atic AI; Thiele M; Munk A; Dalgaard LT
    Am J Physiol Cell Physiol; 2023 Feb; 324(2):C588-C602. PubMed ID: 36645666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum microRNA Levels as a Biomarker for Diagnosing Non-Alcoholic Fatty Liver Disease in Chinese Colorectal Polyp Patients.
    Ng L; Sin RW; Cheung DH; Leung WK; Man AT; Lo OS; Law WL; Foo DC
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.
    Ueno M; Takeda H; Takai A; Seno H
    World J Gastroenterol; 2022 Jul; 28(27):3410-3421. PubMed ID: 36158261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
    Wang L; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease.
    Li J; Delamarre A; Wong VW; de Lédinghen V
    United European Gastroenterol J; 2024 Mar; 12(2):219-225. PubMed ID: 37987101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy.
    D'Abundo L; Bassi C; Callegari E; Moshiri F; Guerriero P; Michilli A; Mora F; Gardini AC; Sangiovanni A; Piscaglia F; Sabbioni S; Gramantieri L; Negrini M
    Sci Rep; 2024 Aug; 14(1):18551. PubMed ID: 39122875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating liver-specific microRNAs as noninvasive diagnostic biomarkers of hepatic diseases in human.
    Musaddaq G; Shahzad N; Ashraf MA; Arshad MI
    Biomarkers; 2019 Mar; 24(2):103-109. PubMed ID: 30252499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma.
    Gori M; Arciello M; Balsano C
    Biomed Res Int; 2014; 2014():741465. PubMed ID: 24745023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.